Innovent Biologics (IVBXF) announced that it has been successfully added as a constituent stock of the Hang Seng Index, HSI, following the release of the Q3 2025 Hang Seng Index Series Quarterly Review results, joining the ranks of blue-chip companies representing Hong Kong’s core assets. “This milestone makes Innovent the first company that has grown from a biotech into a leading biopharma and been included in the HSI,” the company said. The company has been concurrently admitted to the Hang Seng China Enterprises Index, HSCEI, and the Hang Seng ESG Enhanced Index.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVBXF:
- Innovent Biologics’ PECONDLE® Approved for Psoriasis Treatment in China
- Innovent’s Mazdutide 9mg Application Accepted by China’s NMPA
- Innovent Biologics, Sanegene Bio announces results on IBI3016
- Innovent Biologics Achieves 40% Revenue Growth in Q3 2025
- Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating